Strategic Diagnostics Inc.
111 Pencader Drive
Newark,
DE 19702
United States - Map
Phone: 302-456-6789
Fax: 302-456-6770
Web Site: http://www.sdix.com
| Strategic Diagnostics Inc., a biotechnology company, develops, manufactures, and markets antibody products and analytical test kits for food, water, agricultural, industrial, environmental, and scientific applications in the United States and internationally. The company offers life sciences products and custom services that supply critical reagents used in the life science research and development markets. Its life sciences products and services comprise custom antibodies, pre-made catalog antibodies, bulk diagnostic-grade antibodies, proprietary critical reagent products, and associated bio-processing services. The company offers these products and services to pharmaceutical, biotechnology, and diagnostic companies, as well as to biomedical research centers. It also provides industrial biodetection products, including immunoassays, which represents advanced technology for the detection of food pathogens, as well as water and soil contaminants. The companys detection technologies allow industrial customers to identify the presence of adulterants, such as chemical toxins, biological pathogens, and other contaminants, which can compromise human or environmental safety and/or impact efficiencies of production processes. Its products are used in various applications consisting of food and beverage manufacturing, water utilities, and agriculture and agro-science. Strategic Diagnostics markets and sells its products in the life science, food safety, and water quality product categories through a direct sales force, Internet, and a network of distributors, as well as through corporate partners. The company was founded in 1987 and is headquartered in Newark, Delaware. |
|
| Key Statistics |
| |
| | Pay | Exercised | Mr. Francis M. DiNuzzo , 53
Chief Exec. Officer, Pres |
$
353.00K |
$
0 | Dr. James W. Stave Ph.D., 54
Chief Science Officer and VP of R&D |
$
253.00K |
$
0 | Mr. Matthew Knight , 52
Consultant |
$
337.00K |
$
0 | Mr. Kevin J. Bratton , 59
Chief Financial Officer and VP of Fin. |
N/A
| N/A | Dr. David A. Fancy Ph.D.,
Co-Head of Antibody Reagent Production Service |
N/A
| N/A |
|
|
|
Dollar amounts are as of
31-Dec-08
and compensation values are for the last fiscal
year ending on that date. "Pay" is salary, bonuses, etc. "Exercised" is the value of
options exercised during the fiscal year.
| |
|
1.29% Nasdaq 
0.05 (3.70%) 
Profile
